Therapeutic novelties in migraine: new drugs, new hope?

The Journal of Headache and Pain

Thien Phu Do¹  Messoud Ashina¹  Song Guo¹ 

[1] 0000 0001 0674 042X, grid.5254.6, Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;

关键词: Migraine;    Randomized clinical trial;    Efficacy;    Tolerability;    Adverse event;    Ditan;    Gepant;    Antibody;   

DOI  :  10.1186/s10194-019-0974-3

来源: publisher

【 摘 要 】

BackgroundIn the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.Main bodyThe development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.ConclusionCollectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.

【 授权许可】

CC BY